- Home
- SI vs VNDA Comparison
SI vs VNDA Comparison
Compare SI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SI
- VNDA
- Stock Information
- Founded
- SI 2009
- VNDA 2002
- Country
- SI United States
- VNDA United States
- Employees
- SI N/A
- VNDA N/A
- Industry
- SI Medical/Dental Instruments
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- SI Health Care
- VNDA Health Care
- Exchange
- SI Nasdaq
- VNDA Nasdaq
- Market Cap
- SI 248.2M
- VNDA 260.0M
- IPO Year
- SI 2025
- VNDA 2006
- Fundamental
- Price
- SI $14.83
- VNDA $4.81
- Analyst Decision
- SI Strong Buy
- VNDA Strong Buy
- Analyst Count
- SI 5
- VNDA 3
- Target Price
- SI $19.60
- VNDA $14.00
- AVG Volume (30 Days)
- SI 77.6K
- VNDA 996.3K
- Earning Date
- SI 11-11-2025
- VNDA 10-29-2025
- Dividend Yield
- SI N/A
- VNDA N/A
- EPS Growth
- SI N/A
- VNDA N/A
- EPS
- SI N/A
- VNDA N/A
- Revenue
- SI $41,626,000.00
- VNDA $212,074,000.00
- Revenue This Year
- SI $40.62
- VNDA $14.32
- Revenue Next Year
- SI $33.40
- VNDA $37.05
- P/E Ratio
- SI N/A
- VNDA N/A
- Revenue Growth
- SI 115.97
- VNDA 11.12
- 52 Week Low
- SI $10.92
- VNDA $3.81
- 52 Week High
- SI $17.94
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- SI N/A
- VNDA 50.11
- Support Level
- SI N/A
- VNDA $4.28
- Resistance Level
- SI N/A
- VNDA $5.46
- Average True Range (ATR)
- SI 0.00
- VNDA 0.22
- MACD
- SI 0.00
- VNDA 0.06
- Stochastic Oscillator
- SI 0.00
- VNDA 44.12
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.